Genetic testing plays a pivotal role in improving match accuracy by providing detailed information about the genetic mutations present in a patient’s cancer cells. This information can guide the selection of targeted therapies that specifically inhibit the function of these mutations, leading to more effective treatment. For example, patients with BRCA mutations may benefit from PARP inhibitors, while those with HER2-positive breast cancer may respond well to HER2-targeted therapies.
